Lin Bioscience Announces Acceptance Into World-Class Biotech Innovation Labs To Accelerate Product Development

SAN DIEGO, June 15, 2017 /PRNewswire/ -- Lin BioScience, a drug development company specializing in innovative therapies for oncology, ophthalmology, and metabolic diseases, today announced that it will be joining BioLabs and Johnson & Johnson Innovation (JLABS), premier biotech incubators located in La Jolla, California.

Lin BioSciences drug development pipeline currently includes 3 candidates, which target oncology (solid tumors, acute leukemia, brain cancer and metastatic brain cancer from breast and lung cancers) and ophthalmology (dry age-related macular degeneration and Stargardt disease).

Effective April 2017, Lin BioScience has used the two innovation facilities, which include labs, co-working office space, and a life sciences network, to accelerate the development of its pipeline of novel drug candidates targeting unmet medical needs.

BioLabs is a membership-based network of R&D facilities that provides fully-equipped labs and office spaces with unparalleled access to capital and industry partners, and is sponsored by major pharmaceutical companies such as Novartis, Sanofi, and Boehringer Ingelheim. "We're excited to welcome the Lin Bioscience team into BioLabs San Diego's thriving live-science ecosystem, where they'll be working side-by-side with others like them startups with the brightest scientists, the most-promising technologies facing many of the same challenges that every early-stage company goes through," said Susie Harborth, managing director of BioLabs San Diego. "It's a highly selective group; only approximately 20 percent who apply are accepted; but BioLabs members report that the steady stream of ideas and creative exchange that takes place both informally and in our industry-sponsored programming helps move their science forward faster."

Lin BioScience operations are located at JLABS San Diego. JLABS is a 40,000 square-foot life science innovation center, located in La Jolla at the Janssen R&D facility in Torrey Pines. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a "no strings attached" model, Johnson & Johnson Innovation (JJI) does not take an equity stake in the companies occupying JLABS and the companies are free to develop products - either on their own, or by initiating a separate external partnership with JJI or any other company.

"Managing our operations in BioLabs and JLABS will allow us to develop our candidates quickly, and with a high degree of capital efficiency," said Dr. Tom Lin, Chairman and CEO of Lin BioScience. "We are proud and inspired to be associated with BioLabs and JLABS, who are global leaders in biotech innovation."

Lin BioScience's drug development pipeline currently includes 3 candidates, which target oncology (solid tumors, acute leukemia, brain cancer and metastatic brain cancer from breast and lung cancers) and ophthalmology (dry age-related macular degeneration and Stargardt disease).

About Lin BioScience, Inc.
Lin BioScience, Inc. is a drug development company specializing in innovative therapies for diseases with unmet medical needs. Lin BioScience's diverse and novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, and cardiology. For more information, please visit www.linbioscience.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lin-bioscience-announces-acceptance-into-world-class-biotech-innovation-labs-to-accelerate-product-development-300474389.html

SOURCE Lin Bioscience Inc.

Back to news